China National Accord Medicines Valuation
Is 200028 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 200028 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 200028 (HK$14.38) is trading below our estimate of fair value (HK$62.42)
Significantly Below Fair Value: 200028 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 200028?
Key metric: As 200028 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 200028's PE Ratio? | |
|---|---|
| PE Ratio | 11x |
| Earnings | CN¥1.48b |
| Market Cap | CN¥15.12b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.3x |
| Enterprise Value/EBITDA | 9.5x |
| PEG Ratio | 1.8x |
Price to Earnings Ratio vs Peers
How does 200028's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 16.8x | ||
301015 Qingdao Baheal Medical | 20.1x | 21.2% | CN¥14.2b |
600056 China Meheco Group | 19.1x | n/a | CN¥17.2b |
600211 Tibet Rhodiola Pharmaceutical Holding | 15.9x | 25.7% | CN¥11.7b |
600511 China National Medicines | 12x | 9.1% | CN¥26.1b |
200028 China National Accord Medicines | 11x | 6.2% | HK$15.1b |
Price-To-Earnings vs Peers: 200028 is good value based on its Price-To-Earnings Ratio (11x) compared to the peer average (16.8x).
Price to Earnings Ratio vs Industry
How does 200028's PE Ratio compare vs other companies in the CN Healthcare Industry?
| 0 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|
| 0 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: 200028 is good value based on its Price-To-Earnings Ratio (11x) compared to the CN Healthcare industry average (33.1x).
Price to Earnings Ratio vs Fair Ratio
What is 200028's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 11x |
| Fair PE Ratio | 17.6x |
Price-To-Earnings vs Fair Ratio: 200028 is good value based on its Price-To-Earnings Ratio (11x) compared to the estimated Fair Price-To-Earnings Ratio (17.6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Shenzhen Lifotronic Technology
CN¥6.8b
Research, develops, manufactures, and markets medical devices for diagnostics, clinical medicine, skin, and human health related purposes in China.
688389
CN¥15.65
7D
-6.0%
1Y
-35.5%
Innovita Biological Technology
CN¥5.7b
Engages in the research and development, manufacturing, marketing, and sales of POCT rapid diagnostic products.
688253
CN¥41.42
7D
1.5%
1Y
35.8%
Winner Medical
CN¥20.2b
Engages in the research and development, manufacture, and marketing of cotton-based medical dressings and medical disposables, and consumer products in China.
300888
CN¥34.72
7D
4.0%
1Y
-11.5%